Abstract
The homomeric α7 nicotinic receptor (α7 nAChR) is widely expressed in the human brain that could be activated to suppress neuroinflammation, oxidative stress and neuropathic pain. Consequently, a number of α7 nAChR agonists have entered clinical trials as anti-Alzheimer's or anti-psychotic therapies. However, high-resolution crystal structure of the full-length α7 receptor is thus far unavailable. Since acetylcholine-binding protein (AChBP) from Lymnaea stagnalis is most closely related to the α-subunit of nAChRs, it has been used as a template for the N-terminal domain of α-subunit of nAChR to study the molecular recognition process of nAChR-ligand interactions, and to identify ligands with potential nAChR-like activities.
Here we report the discovery and optimization of novel acetylcholine-binding protein ligands through screening, structure-activity relationships and structure-based design. We manually screened in-house CNS-biased compound library in vitro and identified compound 1, a piperidine derivative, as an initial hit with moderate binding affinity against AChBP (17.2% inhibition at 100 nmol/L). During the 1st round of optimization, with compound 2 (21.5% inhibition at 100 nmol/L) as the starting point, 13 piperidine derivatives with different aryl substitutions were synthesized and assayed in vitro. No apparent correlation was demonstrated between the binding affinities and the steric or electrostatic effects of aryl substitutions for most compounds, but compound 14 showed a higher affinity (Ki=105.6 nmol/L) than nicotine (Ki=777 nmol/L). During the 2nd round of optimization, we performed molecular modeling of the putative complex of compound 14 with AChBP, and compared it with the epibatidine-AChBP complex. The results suggested that a different piperidinyl substitution might confer a better fit for epibatidine as the reference compound. Thus, compound 15 was designed and identified as a highly affinitive acetylcholine-binding protein ligand. In this study, through two rounds of optimization, compound 15 (Ki=2.8 nmol/L) has been identified as a novel, piperidine-based acetylcholine-binding protein ligand with a high affinity.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ashford JW . Treatment of Alzheimers disease: the legacy of the cholinergic hypothesis, neuroplasticity, and future directions. J Alzheimers Dis 2015; 47: 149–56.
Bensaid M, Michel PP, Clark SD, Hirsch EC, Francois C . Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinsons disease. Exp Neurol 2016; 275: 209–19.
Müller ML, Bohnen NI . Cholinergic dysfunction in Parkinsons disease. Curr Neurol Neurosci Rep 2013; 13: 377.
Perez XA . Preclinical evidence for a role of the nicotinic cholinergic system in Parkinsons disease. Neuropsychol Rev 2015; 25: 371–83.
Yarnall AJ, Del Din S, David R, Galna B, Baker MR, Burn DJ, et al. Cholinergic deficits contribute to impaired postural control in early Parkinsons disease. Movement Disord 2014; 29: S332–3.
Gibbons A, Dean B . The cholinergic system: an emerging drug target for schizophrenia. Curr Pharm Des 2016; 22: 2124–33.
Sarter M, Lustig C, Taylor SF . Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology 2012; 62: 1544–53.
Scarr E, Dean B . Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Rev Neurother 2009; 9: 73–86.
Han Z, Li L, Wang L, Degos V, Maze M, Su H . Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture. J Neurochem 2014; 131: 498–508.
Skok M, Lykhmus O . The role of alpha 7 nicotinic acetylcholine receptors and alpha 7-specific antibodies in neuroinflammation related to Alzheimer disease. Curr Pharm Design 2016; 22: 2035–49.
Han Z, Shen F, He Y, Degos V, Camus M, Maze M, et al. Activation of alpha-7 nicotinic acetylcholine receptor reduces ischemic stroke injury through reduction of pro-inflammatory macrophages and oxidative stress. PLoS One 2014; 9: e105711.
Loram LC, Taylor FR, Strand KA, Maier SF, Speake JD, Jordan KG, et al. Systemic administration of an alpha-7 nicotinic acetylcholine agonist reverses neuropathic pain in male Sprague Dawley rats. J Pain 2012; 13: 1162–71.
Nikiforuk A, Kos T, Holuj M, Potasiewicz A, Popik P . Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats. Neuropharmacology 2016; 101: 389–400.
Bencherif M, Stachowiak MK, Kucinski AJ, Lippiello PM . Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. Med Hypotheses 2012; 78: 594–600.
Young JW, Geyer MA . Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol 2013; 86: 1122–32.
Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 2005; 76: 67–72.
Hashimoto K . Targeting of alpha 7 nicotinic acetylcholine receptors in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker. Curr Pharm Design 2015; 21: 3797–806.
Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiat 2008; 165: 1040–7.
Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, et al. Proof-of-concept trial of an alpha 7 nicotinic agonist in schizophrenia. Arch Gen Psychiat 2006; 63: 630–8.
Hosford D, Dvergsten C, Beaver J, Segreti AC, Toler S, Farr MG, et al. Phase 2 clinical trial of TC-5619, an alpha 7 nicotinic receptor agonist in the treatment of negative and cognitive symptoms in schizophrenia. Eur Neuropsychopharm 2014; 24: S531–2.
Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013; 38: 968–75.
Mazurov AA, Kombo DC, Hauser TA, Miao L, Dull G, Genus JF, et al. Discovery of (2S,3R)-N-[2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective alpha 7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders. J Med Chem 2012; 55: 9793–809.
Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC . Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract 2014; 20: 12–23.
Kuca K, Soukup O, Maresova P, Korabecny J, Nepovimova E, Klimova B, et al. Current approaches against Alzheimer's disease in clinical trials. J Brazil Chem Soc 2016; 27: 641–9.
Di Paolo T, Gregoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B . AQW051, a novel and selective nicotinic acetylcholine receptor alpha 7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord 2014; 20: 1119–23.
Wu ZS, Cheng H, Jiang Y, Melcher K, Xu HE . Ion channels gated by acetylcholine and serotonin: structures, biology, and drug discovery. Acta Pharmacol Sin 2015; 36: 895–907.
Spurny R, Debaveye S, Farinha A, Veys K, Vos AM, Gossas T, et al. Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the alpha 7 nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A 2015; 112: E2543–52.
Sauguet L, Shahsavar A, Poitevin F, Huon C, Menny A, Nemecz A, et al. Crystal structures of a pentameric ligand-gated ion channel provide a mechanism for activation. Proc Natl Acad Sci U S A 2014; 111: 966–71.
Chiodo L, Malliavin TE, Maragliano L, Cottone G, Ciccotti G . A structural model of the human alpha 7 nicotinic receptor in an open conformation. PLoS One 2015; 10: e0133011.
Beck ME, Gutbrod O, Matthiesen S . Insight into the binding mode of agonists of the nicotinic acetylcholine receptor from calculated electron densities. Chemphyschem 2015; 16: 2760–7.
Hu ZJ, Bai L, Tizabi Y, Southerland W . Computational modeling study of human nicotinic acetylcholine receptor for developing new drugs in the treatment of alcoholism. Interdiscip Sci 2009; 1: 254–62.
Smit AB, Syed NI, Schaap D, van Minnen J, Klumperman J, Kits KS, et al. A glia-derived acetylcholine-binding protein that modulates synaptic transmission. Nature 2001; 411: 261–8.
Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van der Oost J, Smit AB, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001; 411: 269–76.
Stornaiuolo M, De Kloe GE, Rucktooa P, Fish A, van Elk R, Edink ES, et al. Assembly of a pi-pi stack of ligands in the binding site of an acetylcholine-binding protein. Nat Commun 2013; 4: 1875.
Rucktooa P, Smit AB, Sixma TK . Insight in nAChR subtype selectivity from AChBP crystal structures. Biochem Pharmacol 2009; 78: 777–87.
Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, Bourne Y . Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. EMBO J 2005; 24: 3635–46.
Celie PH, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB, Sixma TK . Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 2004; 41: 907–14.
Yamauchi JG, Gomez K, Grimster N, Dufouil M, Nemecz A, Fotsing JR, et al. Synthesis of selective agonists for the alpha 7 nicotinic acetylcholine receptor with in situ click-chemistry on acetylcholine-binding protein templates. Mol Pharmacol 2012; 82: 687–99.
Smit AB, Ulens C . From structure and function analysis in AChBP to drug design. FEBS J 2013; 280: 184.
Edink E, Akdemir A, Jansen C, van Elk R, Zuiderveld O, de Kanter FJJ, et al. Structure-based design, synthesis and structure-activity relationships of dibenzosuberyl- and benzoate-substituted tropines as ligands for acetylcholine-binding protein. Bioorg Med Chem Lett 2012; 22: 1448–54.
de Kloe GE, Retra K, Geitmann M, Kallblad P, Nahar T, van Elk R, et al. Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor alpha 7 ligands. J Med Chem 2010; 53: 7192–201.
Gundisch D, Eibl C . Nicotinic acetylcholine receptor ligands, a patent review (2006–2011). Expert Opin Ther Pat 2011; 21: 1867–96.
Yenugonda VM, Xiao YX, Levin ED, Rezvani AH, Tran T, Al-Muhtasib N, et al. Design, synthesis and discovery of picomolar selective alpha 4 beta 2 nicotinic acetylcholine receptor ligands. J Med Chem 2013; 56: 8404–21.
Zhang HK, Yu LF, Eaton JB, Whiteaker P, Onajole OK, Hanania T, et al. Chemistry, pharmacology, and behavioral studies identify chiral cyclopropanes as selective alpha 4 beta 2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile. Part II. J Med Chem 2013; 56: 5495–504.
Jensen AA, Frolund B, Liljefors T, Krogsgaard-Larsen P . Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 2005; 48: 4705–45.
Li SX, Huang S, Bren N, Noridomi K, Dellisanti CD, Sine SM, et al. Ligand-binding domain of an alpha7-nicotinic receptor chimera and its complex with agonist. Nat Neurosci 2011; 14: 1253–9.
Acknowledgements
This work was supported by the Science and Technology Commission of Shanghai Municipality (No 15431900100) and the National Natural Science Foundation of China (No 81473076).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary information is available on the Acta Pharmacologica Sinica's website.
Supplementary information
Supplementary Information
Detailed analytical information (DOC 848 kb)
Rights and permissions
About this article
Cite this article
Shen, J., Yang, Xc., Yu, Mc. et al. Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands. Acta Pharmacol Sin 38, 146–155 (2017). https://doi.org/10.1038/aps.2016.124
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2016.124
